Related Experiment Video

Updated: Aug 9, 2025

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.4K

A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia

Joseph Dao1, Savreen Saran1, Melody Wang1

  • 1College of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA.

Brain Sciences
|February 25, 2023
PubMed

Insights

Patients with schizophrenia face higher cardiovascular disease (CVD) risks. This review highlights the lack of research on aspirin (ASA) use for CVD prevention in schizophrenia patients, indicating a critical need for further investigation.

Area of Science:

  • Cardiology
  • Psychiatry
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is the leading global cause of mortality.
  • Patients with schizophrenia (SCZ) exhibit a significantly elevated risk of developing CVD.
  • Current treatments like metformin and statins show limited efficacy in mitigating CVD risk in SCZ patients.

Purpose of the Study:

  • To systematically review existing literature on the utilization of aspirin (ASA) for cardiovascular risk reduction in patients with schizophrenia.
  • To identify gaps in current research regarding CVD preventative strategies in the SCZ population.

Main Methods:

  • A systematic literature review was conducted to assess studies investigating CVD risk and preventative treatments in SCZ.
  • The review focused on identifying any research pertaining to the use of aspirin (ASA) as an adjuvant therapy for CVD prevention in SCZ.

Main Results:

  • The review identified a substantial body of evidence confirming increased CVD risk in individuals with SCZ.
  • Crucially, no studies were found that specifically examined the use of aspirin (ASA) for CVD prevention in SCZ patients.

Conclusions:

  • There are significant gaps in the literature concerning CVD prevention strategies for schizophrenia patients.
  • Further research is urgently needed to explore the potential benefits of treatments like aspirin (ASA) in reducing CVD risk and mortality in this vulnerable population.

Keywords:
anti-inflammatoryaspirincardiovascularmental-healthmetabolicschizophrenia

More Related Videos

Development of a Virtual Reality Assessment of Everyday Living Skills10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.5K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

Related Concept Videos

Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
158
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
812
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
111
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
479
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
82
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
180